In a new paper, the Biotechnology Industry Organization reveals it has reservations about the use of comparative effectiveness in reviewing products.
The Biotechnology Industry Organization has issued a white paper on comparative effectiveness. Authored by BIO's director of economic policy Ted Buckley, Ph.D., the document maintains that while comparative effectiveness is a helpful tool for healthcare decision-makers when comparing different products, it cannot be used to provide one-size-fits-all answers. The report can be found on